“The decision to approve the vaccine was made by the decree of the Ministry of Health based on the data of phase III clinical trials in Russia without additional trials in Armenia,” the statement says.
RDIF recalled that Sputnik V is currently registered in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, the United Arab Emirates, Iran, the Republic of Guinea and Tunisia.
Earlier, the French government noted that the Sputnik V vaccine could be offered to the French if European and French regulators confirm its safety and effectiveness.